REFERENCES:
1. Al-Khatib Sana M., Stevenson William G., Ackerman Michael J., Bryant
William J., Callans David J., Curtis Anne B., et al. 2017 AHA/ACC/HRS
Guideline for management of patients with ventricular arrhythmias and
the prevention of sudden cardiac death. Circulation. 2018 Sep
25;138(13):e272–391.
2. Naksuk N, Saab A, Li J-M, Florea V, Akkaya M, Anand IS, et al.
Incidence of appropriate shock in implantable cardioverter-defibrillator
patients with improved ejection fraction. J Card Fail. 2013
Jun;19(6):426–30.
3. Kini V, Soufi MK, Deo R, Epstein AE, Bala R, Riley M, et al.
Appropriateness of primary prevention implantable
cardioverter-defibrillators at the time of generator replacement. J Am
Coll Cardiol. 2014 Jun 10;63(22):2388–94.
4. Zhang Y, Guallar E, Blasco-Colmenares E, Butcher B, Norgard S,
Nauffal V, et al. Changes in follow-up left ventricular ejection
fraction associated with outcomes in primary prevention ICD and CRT-D
recipients. J Am Coll Cardiol. 2015 Aug 4;66(5):524–31.
5. Vakil K, Florea V, Koene R, Kealhofer JV, Anand I, Adabag S. Effect
of Coronary Artery Bypass Grafting on Left Ventricular Ejection Fraction
in Men Eligible for Implantable Cardioverter-Defibrillator. Am J
Cardiol. 2016 Mar 15;117(6):957–60.
6. Madhavan M, Waks JW, Friedman PA, Kramer DB, Buxton AE, Noseworthy
PA, et al. Outcomes After Implantable Cardioverter-Defibrillator
Generator Replacement for Primary Prevention of Sudden Cardiac Death.
Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e003283.
7. Adabag S, Patton KK, Buxton AE, Rector TS, Ensrud KE, Vakil K, et al.
Association of implantable cardioverter defibrillators with survival in
patients with and without improved ejection fraction. JAMA Cardiol. 2017
Jul;2(7):767–74.
8. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al.
Amiodarone or an implantable cardioverter-defibrillator for congestive
heart failure. N Engl J Med. 2005 Jan 20;352(3):225–37.
9. Bardy G, Lee K, Mark D, Poole J, Fishbein D. The Sudden Cardiac
Death–Heart Failure Trial (SCD-HeFT). In: In: Woosley RL, Singh SN,
editors Arrhythmia Treatment and Therapy: Evaluation of Clinical Trial
Evidence. New York: Marcel Dekker; 2000. p. 323–42.
10. BioLINCC - Biologic Specimen and Data Repository Information
Coordinating Center [Internet]. [cited 2020 Mar 8]. Available
from: https://biolincc.nhlbi.nih.gov/home/
11. Ruwald Martin H., Solomon Scott D., Foster Elyse, Kutyifa Valentina,
Ruwald Anne-Christine, Sherazi Saadia, et al. Left Ventricular Ejection
Fraction Normalization in Cardiac Resynchronization Therapy and Risk of
Ventricular Arrhythmias and Clinical Outcomes. Circulation. 2014 Dec
1;130(25):2278–86.
12. Lupón J, Gavidia-Bovadilla G, Ferrer E, de Antonio M, Perera-Lluna
A, López-Ayerbe J, et al. Dynamic trajectories of left ventricular
ejection fraction in heart failure. J Am Coll Cardiol. 2018
Aug;72(6):591–601.
13. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al.
Association of fibrosis with mortality and sudden cardiac death in
patients with nonischemic dilated cardiomyopathy. JAMA. 2013 Mar
6;309(9):896–908.
14. Anantha Narayanan M, Vakil K, Reddy YN, Baskaran J, Deshmukh A,
Benditt DG, et al. Efficacy of Implantable Cardioverter-Defibrillator
Therapy in Patients With Nonischemic Cardiomyopathy: A Systematic Review
and Meta-Analysis of Randomized Controlled Trials. JACC Clin
Electrophysiol. 2017;3(9):962–70.
15. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al.
Defibrillator Implantation in Patients with Nonischemic Systolic Heart
Failure. N Engl J Med. 2016 29;375(13):1221–30.
16. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S,
et al. Withdrawal of pharmacological treatment for heart failure in
patients with recovered dilated cardiomyopathy (TRED-HF): an open-label,
pilot, randomised trial. Lancet Lond Engl. 2019 Jan 5;393(10166):61–73.
17. Cioffi G, Stefenelli C, Tarantini L, Opasich C. Chronic left
ventricular failure in the community: prevalence, prognosis, and
predictors of the complete clinical recovery with return of cardiac size
and function to normal in patients undergoing optimal therapy. J Card
Fail. 2004 Jun;10(3):250–7.
18. Adabag S, Smith LG, Anand IS, Berger AK, Luepker RV. Sudden cardiac
death in heart failure patients with preserved ejection fraction. J Card
Fail. 2012 Oct;18(10):749–54.
19. Adabag S, Langsetmo L. Sudden cardiac death risk prediction in heart
failure with preserved ejection fraction. Heart Rhythm. 2020
Mar;17(3):358–64.
20. Adabag S, Rector TS, Anand IS, McMurray JJ, Zile M, Komajda M, et
al. A prediction model for sudden cardiac death in patients with heart
failure and preserved ejection fraction. Eur J Heart Fail. 2014
Nov;16(11):1175–82.
21. Pellikka PA, She L, Holly TA, Lin G, Varadarajan P, Pai RG, et al.
Variability in Ejection Fraction Measured By Echocardiography, Gated
Single-Photon Emission Computed Tomography, and Cardiac Magnetic
Resonance in Patients With Coronary Artery Disease and Left Ventricular
Dysfunction. JAMA Netw Open. 2018 03;1(4):e181456.